The MSC-EV-microRNAome: a perspective on therapeutic mechanisms of action in sepsis and ARDS

Claudia C. dos Santos, Miquéias Lopes-Pacheco, Karen English, Sara Rolandsson Enes, Anna Krasnodembskaya, Patricia Rocco

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
32 Downloads (Pure)


Mesenchymal stromal cells (MSCs) and MSC-derived extracellular vesicles (EVs) have emerged as innovative therapeutic agents for the treatment of sepsis and acute respiratory distress syndrome (ARDS). Although their potential remains undisputed in pre-clinical models, this has yet to be translated to the clinic. In this review, we focused on the role of microRNAs contained in MSC-derived EVs, the EV microRNAome, and their potential contribution to therapeutic mechanisms of action. The evidence that miRNA transfer in MSC-derived EVs has a role in the overall therapeutic effects is compelling. However, several questions remain regarding how to reconcile the stochiometric issue of the low copy numbers of the miRNAs present in the EV particles, how different miRNAs delivered simultaneously interact with their targets within recipient cells, and the best miRNA or combination of miRNAs to use as therapy, potency markers, and biomarkers of efficacy in the clinic. Here, we offer a molecular genetics and systems biology perspective on the function of EV microRNAs, their contribution to mechanisms of action, and their therapeutic potential.

Original languageEnglish
Article number122
Number of pages19
Issue number2
Publication statusPublished - 09 Jan 2024


Dive into the research topics of 'The MSC-EV-microRNAome: a perspective on therapeutic mechanisms of action in sepsis and ARDS'. Together they form a unique fingerprint.

Cite this